看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。 i K9 u1 I, N9 X, b
( x5 i/ b9 Y2 W/ P0 `4 y! c* e6 `+ G4 W8 _
Currently available feasibility data for possible combination strategies.
; `$ d: g" I Y& x- _————————————————————————————————- _- B. Y8 N {* t! R2 Q
Combination Feasibility according to preliminary data ' k" h' E. K E# N0 B
——————————————————————————————————
2 q: E! |' i8 }+ i% XBevacizumab + sorafenib Yes, reduced dose * m. W1 \, S/ t- t# r3 O
Bevacizumab + sunitinib† No : M0 {# t0 |3 k W) w$ y
Bevacizumab + temsirolimus Yes
( p! ?" V- K! j8 bBevacizumab + everolimus Yes
: j% r3 s, U4 l3 @Sorafenib + sunitinib ?
: K, R% x% w! j$ ?" z' D9 ZSorafenib + temsirolimus Yes, reduced dose
5 U1 f* j4 O3 r. m/ {. zSorafenib + everolimus Yes, reduced dose
5 t0 h4 s: m+ h/ ?7 K9 ~Sunitinib + temsirolimus† No ; w/ D( W( I# S& r: j. M
Sunitinib + everolimus ? / L% |. n7 Z7 N# b
Temsirolimus + everolimus ? 1 P/ D1 x: h# y) V
————————————————————3 M8 D5 [3 H* H' s) c( X
†Led to US FDA warning.3 y/ a; h6 h" r4 K7 |* t' ?* X
?: As yet unattempted combination.) C- G- g# a4 C6 U% {* v
|